What's in Aegerion Pharmaceuticals, Inc.'s pipeline?

Aegerion Pharmaceuticals, Inc. has 4 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 3 in Phase 2, 0 in Phase 1.

Which companies overlap with Aegerion Pharmaceuticals, Inc.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/aegerion-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Aegerion Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Aegerion Pharmaceuticals, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
AEGR-733	AEGR-733	phase 3	MTP inhibitor	Microsomal triglyceride transfer protein (MTP)	Cardiovascular / Lipidology

Therapeutic area mix

Cardiovascular · 2
Cardiovascular / Lipidology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Aegerion Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Aegerion Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aegerion-pharmaceuticals-inc. Accessed 2026-05-16.